May 25, 2017
Recommended Topic Related To:


"Rebound growth of infantile hemangiomas (IHs) may occur in up to a quarter of patients treated with oral propranolol (OP) therapy, and early discontinuation of therapy may double this risk, according to a new retrospective study. These findings a"...



Side Effects


Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The overall safety of SITAVIG was assessed in 378 adult subjects having at least 4 herpes labialis episodes the previous year.

One randomized, double-blind, placebo controlled trial was conducted in patients with recurrent herpes labialis (cold sores). In this trial, 378 HSV infected subjects used SITAVIG as a single dose, and 397 subjects used placebo.

Selected treatment emergent adverse events without regard to causality and reported in at least 1% of patients can be seen in Table 1.

Table 1 : Selected Treatment Emergent Adverse Events reported in at least 1% of patients

N = 378
N = 397
Nervous System Disorders
Headache 3% 3%
Dizziness 1% 1%
Lethargy 1% 0
Gastrointestinal system Disorders
Gingival Pain 1% 0.3%
Aphthous Stomatitis 1% 0
Administration Site Conditions
Application Site Pain 1% 1%
Application Site Irritation 1% 0
Skin and Subcutaneous Disorders
Erythema 1% 0.3%
Rash 1% 0.3%

The treatment emergent adverse events considered related to treatment that occurred in greater than or equal to 1% of patients included headache (1% SITAVIG vs. 2% placebo) and application site pain (1% both arms). There was no discontinuation of SITAVIG due to adverse drug reactions. Most treatment related adverse events were mild or moderate in severity. One report of headache from both treatment arms was classified as severe.

Read the Sitavig (acyclovir buccal tablets) Side Effects Center for a complete guide to possible side effects


No interaction studies have been performed with SITAVIG. Acyclovir is primarily eliminated unchanged in the urine via active tubular secretion. Drugs administered concomitantly that compete with tubular secretion may increase acyclovir plasma concentrations. However, due to the low dose and minimal systemic absorption of SITAVIG, systemic drug interactions are unlikely.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 10/31/2016

Side Effects

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.